News & Updates
Filter by Specialty:
Updated ASCEMBL results boost asciminib potential for CML
In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).
Updated ASCEMBL results boost asciminib potential for CML
28 Jun 2022PPIs raise death risk in advanced NSCLC patients on antitumour therapy
Treatment with proton pump inhibitors (PPI) appears to increase the risk of mortality among patients with advanced nonsmall cell lung cancer (NSCLC) undergoing systemic antitumour therapy, reveals a recent study.
PPIs raise death risk in advanced NSCLC patients on antitumour therapy
25 Jun 2022KangDuo Surgical Robot-01 system feasible for robot-assisted radical prostatectomy
Use of the KangDuo Surgical Robot-01 (KD-SR-01) system for the management of localized prostate cancer is safe and effective, according to the initial results of a prospective, single-centre study.
KangDuo Surgical Robot-01 system feasible for robot-assisted radical prostatectomy
24 Jun 2022Colorectal cancer alters gut microbiome
Patients with colorectal cancer (CRC) have a substantially altered gut microbiome, characterized by changes in bacterial composition, according to a recent Singapore study. Of note, these alterations persist even after surgery.
Colorectal cancer alters gut microbiome
24 Jun 2022Negative transrectal ultrasound biopsy tied to low prostate cancer death
Prostate cancer-specific mortality is very low among men with negative transrectal ultrasound (TRUS) biopsies, particularly those with prostate-specific antigen (PSA) <10 ng/ml, reports a study.